GAMMA Investing’s Verve Therapeutics VERV Stock Holding History

GAMMA Investing’s Portfolio VERV Stock Details VERV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-165	Closed	-$1.85K	–	3932
2025 Q2	$1.85K	Sell	165 -7,174	-98%	-$40.9K	﹤0.01%	3423
2025 Q1	$33.5K	Buy	7,339 +1,285	+21%	+$8.61K	﹤0.01%	2070
2024 Q4	$34.1K	Buy	6,054 +3,964	+190%	+$22.4K	﹤0.01%	1961
2024 Q3	$10.1K	Sell	2,090 -15,033	-88%	-$87.3K	﹤0.01%	2456
2024 Q2	$83.6K	Buy	17,123 +16,397	+2,259%	+$103K	0.01%	873
2024 Q1	$9.64K	Buy	726 +631	+664%	+$8.37K	﹤0.01%	2086
2023 Q4	$1.03K	Buy	+95	New	+$1.18K	﹤0.01%	2780

Other funds holding VERV

GCM

Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

BIG

Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

GAMMA Investing's VERV Position: Q3 2025 in Review

GAMMA Investing sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 165 shares — an estimated $1.85K sold.

GAMMA Investing first reported a position in VERV in Q4 2023 and held it in 7 quarters. The position peaked at $83.6K in Q2 2024. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

GAMMA Investing reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
GAMMA Investing sold 165 Verve Therapeutics shares in Q3 2025, an estimated $1.85K.
GAMMA Investing first reported a position in Verve Therapeutics in Q4 2023 and held it in 7 quarters.
GAMMA Investing's Verve Therapeutics position peaked at $83.6K in Q2 2024.
6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on GAMMA Investing's 13F filing for Q3 2025, filed 2 Oct 2025.